Obviously we don't know whether they are planning to license PI-88 for individual cancers or a package - but if they are seeking to license individually as you point out they have completed Phase II Efficacy endpoint for Multiple Myeloma, which although is not a major cancer in the scheme of things - about 1% of all cancers, is still a major disease with about 13,000 people diagnosed in the UsA alone each year.
http://www.nci.nih.gov/cancer_information/doc_wyntk.aspx?viewid=5db34eef-d9c1-47dd-94e1-3c98099798ba
drug pi-88, melanoma; how good is it?, page-4
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PGL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.30M | |||
| Open | High | Low | Value | Volume |
| 44.5¢ | 44.5¢ | 44.0¢ | $226.2K | 509.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 158238 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 257803 | 9 |
View Market Depth
| Last trade - 15.23pm 23/07/2024 (20 minute delay) ? |
| PGL (ASX) Chart |